SummitTX Capital L.P. Has $2.03 Million Stake in Immunome, Inc. $IMNM

SummitTX Capital L.P. decreased its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 27.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 92,880 shares of the company’s stock after selling 34,733 shares during the quarter. SummitTX Capital L.P. owned 0.08% of Immunome worth $2,031,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. KBC Group NV bought a new stake in shares of Immunome in the first quarter valued at about $60,000. BNP Paribas Financial Markets increased its stake in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the period. Strs Ohio bought a new position in Immunome during the fourth quarter valued at about $64,000. Tower Research Capital LLC TRC raised its holdings in Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after acquiring an additional 3,802 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Immunome in the 3rd quarter valued at approximately $76,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Transactions at Immunome

In other news, insider Robert Lechleider sold 55,000 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total value of $1,244,100.00. Following the sale, the insider owned 15,805 shares in the company, valued at approximately $357,509.10. The trade was a 77.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 60,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the completion of the sale, the chief financial officer directly owned 54,037 shares in the company, valued at approximately $985,094.51. The trade was a 52.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 472,142 shares of company stock valued at $10,262,648. 7.21% of the stock is owned by insiders.

Immunome Trading Up 2.8%

NASDAQ IMNM opened at $23.22 on Wednesday. Immunome, Inc. has a 1-year low of $8.66 and a 1-year high of $27.65. The company has a market capitalization of $2.63 billion, a price-to-earnings ratio of -9.76 and a beta of 2.07. The stock’s 50 day moving average is $21.15 and its two-hundred day moving average is $22.00.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Analysts Set New Price Targets

IMNM has been the subject of a number of research reports. Citigroup reiterated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a research report on Tuesday, July 21st. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immunome has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.